About Onconova
Onconova is a publicly listed company based in Newtown Square (United States) founded in 1998. Small molecule inhibitors are developed for cancer and MDS treatments. Onconova has raised $157.75 million across 17 funding rounds from investors including Baxter, HHS and Ben Franklin Technology Partners. The company has 17 employees. Onconova has completed 1 acquisition, including Trawsfynydd Therapeutics. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Onconova is a developer of small molecule inhibitors to treat Myelodysplastic syndrome and other cancers. It is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created a library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. Lead candidate is Rigosertib, which is in advanced clinical development for the treatment of higher-risk myelodysplastic syndromes (MDS). MDS is a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukemia (AML).
- Headquarters Newtown Square, United States
- Employees 17
- Stage Public
- SectorsHealthcare
- Website onconova.com
- Social LinkedIn
- Annual Revenue$226 K (USD)as on Dec 31, 2022
- Net Profit-$18.96 M (USD)-17as on Dec 31, 2022
- EBITDA-$19.63 M (USD)-19as on Dec 31, 2022
- Total Equity Funding$157.75M (USD)
in 17 rounds
- Latest Funding Round$500K (USD), Post-IPO
Jun 2019
- InvestorsBaxter
& 2 more
- Employee Count17
- Investments & Acquisitions
Funding Insights of Onconova
Onconova has successfully raised a total of $157.75M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 thousand completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $157.75M
- Total Rounds 17
- Last Round Post-IPO — $500,000
- First Round $3.81M
(Jun 2003)
- Investors Count 3
Latest 10 of 17 funding rounds of Onconova with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $500,000 | Post-IPO | – | – | – |
| May 2018 | $1.25M | Post-IPO | – | – | – |
| Jan 2016 | $1.84M | Post-IPO | – | – | – |
| Oct 2015 | $1.5M | Post-IPO | – | – | – |
| Aug 2012 | $50M | Series E | – | Baxter | – |
| Jul 2012 | $26.44M | Series E | – | – | – |
| Sep 2011 | $275,861 | Grant | – | – | |
| Jan 2011 | $11.69M | Series D | – | – | – |
| Mar 2010 | $19.23M | Series D | – | – | – |
| Mar 2009 | $250,000 | Series C | – | Ben Franklin Technology Partners | – |
3 investors in total: 3 institutional.
Investors in Onconova
Onconova has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Baxter, HHS and Ben Franklin Technology Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Technology ecosystem growth is supported in Southeastern Pennsylvania. | sep.benfranklin.org | Philadelphia, United States | ||
Biosciences, medication delivery, and renal products are developed and marketed. | 1931 | baxter.com | Deerfield, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Onconova
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Onconova
9 people are tracked at Onconova (2 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 17.
| Name | Role | Group |
|---|---|---|
Victor Moyo | Consulting Chief Medical Officer | Leadership |
Mark Gelder | Chief Medical Officer | Leadership |
Jerome Groopman | Board Member | Board & advisors |
James J. Marino | Chairman | Board & advisors |
Viren Mehta | Board Member | Board & advisors |
Jack E. Stover | Board Member | Board & advisors |
M. Teresa Shoemaker | Board Member | Board & advisors |
Peter Atadja | Board Member | Board & advisors |
Stephen Cosenza | Lead Scientist & Study Monitor | Team |
Complete people profiles for Onconova
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Onconova
Onconova has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Trawsfynydd Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antiviral therapies for influenza and COVID-19 are developed. | trawsfynyddther.com | Rockville, United States | 2024 | Apr 2024 | •••• |
Complete acquisition details for Onconova
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Onconova
5 dated milestones of Onconova across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Onconova is founded.
- Funding First funding round of $3.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $500K.
- Acquisition Acquires Trawsfynydd Therapeutics.
Web traffic of Onconova
Websites that share an audience with Onconova (onconova.com).
Websites whose visitors overlap most with Onconova. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| unither.com | 100% | 32.2K | #968,866 | View details | |
| seattlegenetics.com | 95% | View details | |||
| orexigen.com | 95% | View details | |||
| covance.com | 95% | 20.2K | #688,229 | View details | |
ert.com | ert.com | 95% | #277,463 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Onconova
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Onconova (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Onconova
Complete news archive for Onconova
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Onconova
Onconova was founded in 1998 and raised its 1st funding round 5 years after it was founded.
Onconova is headquartered in Newtown Square, United States. It is registered at Newtown Square, Pennsylvania, United States.
Onconova is a funded company, having raised a total of $157.75M across 17 funding rounds to date. The company's 1st funding round was a Series C of $250K, raised on Jun 2003.
Onconova has 17 employees.
Annual revenue of Onconova is $226K as on Dec 31, 2022.
Onconova is a developer of small molecule inhibitors to treat Myelodysplastic syndrome and other cancers. It is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created a library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. Lead candidate is Rigosertib, which is in advanced clinical development for the treatment of higher-risk myelodysplastic syndromes (MDS). MDS is a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukemia (AML).
Onconova has made 1 acquisition, including Trawsfynydd Therapeutics.
Onconova has 3 investors. Key investors include Baxter, HHS, and Ben Franklin Technology Partners.